Business
Stella Diagnostics Announces Leadership Changes: Dr. Joe Abdo Assumes a New Role as Chief Scientific Officer, and Director David Seaburg is Appointed Chief Executive Officer
Stella Diagnostics Announces Leadership Changes: Dr. Joe Abdo Assumes a New Role as Chief Scientific Officer, and Director David Seaburg is Appointed Chief Executive Officer.
About this update from Stella Diagnostics Inc.
[{"type":"text","content":"\n SALT LAKE CITY, April 22, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancerous esophageal diseases, today announced leadership changes in conjunction with the next phase of its business plan. In order to successfully implement new processes, products, and business strategies, Dr. Joe Abdo will assume the newly created position of Chief Scientific Officer, and David Seaburg, who is currently a member of Stella Diagnostics’ Board of Directors, has been appointed Chief Executive Officer. The planned leadership transition reflects Stella Diagnostics’ Board of Directors succession planning process. Accordingly, the Board conducted a comprehensive evaluation of internal and external candidates. Following a thorough assessment, the Board unanimously determined the leadership changes. Daniel Wainstein, Chairman of Stella Diagnostics' Board of Directors, said, “This leadership transition marks an important inflection point for Stella Diagnostics, since it will provide both Joe and David the opportunity to focus on the areas they know best. Since coming on board as a Director, David has been a key member of our leadership team. Joe has proven himself as a strong leader with an extensive knowledge of molecular oncology research and precancerous and cancerous esophageal diseases. The Board looks forward to working with David, Joe, and the rest of management to drive our strategy forward and continuing to create meaningful value for shareholders.” David Seaburg brings extensive global commercialization and finance skills from executive leadership roles in his distinguished career on Wall Street. Mr. Seaburg has most recently served as President and CEO of PolarityTe, Inc. Prior to becoming President and CEO, he served as President of Corporate Development while serving on the company’s Board of Directors. During his 25-year career on Wall Street, Mr. Seaburg served as the Managing Director and Head of Sales Trading at Cowen & Company, a diversified financial services company with a focus on biotech and healthcare issuance. In 2006, Mr. Seaburg was named Head of Sales Trading and appointed to the firm’s Equity Operating Committee. Mr. Seaburg was a CNBC Fast Money Contributor a...